Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12178.154 | 1.0593 | 1.2358 | 0.5170 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12178.154 | 1.0227 | 1.0889 | 0.5170 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12178.154 | 0.9373 | 0.7645 | 0.5170 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12178.154 | 0.8505 | 0.4622 | 0.5170 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12178.154 | 0.6885 | -0.0286 | 0.5170 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12178.154 | 0.4314 | -0.6067 | 0.5170 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12178.154 | 0.0150 | -0.9994 | 0.5170 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12291.167 | 0.9409 | 0.8113 | 0.6147 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12291.167 | 0.8806 | 0.6262 | 0.6147 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12291.167 | 0.9728 | 0.9124 | 0.6147 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12291.167 | 0.9613 | 0.8757 | 0.6147 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12291.167 | 0.9060 | 0.7033 | 0.6147 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12291.167 | 0.8318 | 0.4821 | 0.6147 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12291.167 | 0.5527 | -0.2377 | 0.6147 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12291.167 | 0.3613 | -0.6183 | 0.6147 | |
| BT-474 | HER2amp | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12291.167 | 0.0119 | -0.9985 | 0.6147 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 10696.154 | 1.0045 | 1.0148 | 0.6070 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 10696.154 | 0.9944 | 0.9815 | 0.6070 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 10696.154 | 1.0024 | 1.0080 | 0.6070 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 10696.154 | 1.0232 | 1.0771 | 0.6070 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 10696.154 | 0.9972 | 0.9909 | 0.6070 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 10696.154 | 0.9017 | 0.6865 | 0.6070 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 10696.154 | 0.8331 | 0.4806 | 0.6070 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 10696.154 | 0.5907 | -0.1599 | 0.6070 | |
| BT-483 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 10696.154 | 0.4621 | -0.4393 | 0.6070 |